Alphatec Holdings stock faces heavy selling pressure following a disappointing 2026 revenue forecast cut to $862 million, triggered by ongoing supply chain headwinds.
Alphatec Holdings experienced a significant decline in share price following the downward revision of its 2026 revenue guidance to $862 million. The company explicitly attributed this shortfall to operational supply chain constraints affecting its biologics, thoracolumbar, and international business segments. This negative outlook has triggered a formal shareholder investigation regarding potential misrepresentations or failures in corporate disclosures.
The company has adjusted its full-year 2026 revenue outlook to approximately $862 million.
The reduction is attributed to supply pressures specifically impacting the biologics, thoracolumbar, and international segments.
Alphatec Holdings shares plummeted after the company slashed its 2026 revenue guidance to $862 million. Management attributed the downward revision to persistent supply chain constraints across its biologics, thoracolumbar, and international segments.
The company cited significant supply chain pressures affecting its biologics, thoracolumbar, and international product lines.